225 related articles for article (PubMed ID: 16531282)
1. Apoptosis inhibitor, survivin, in posterior uveal melanoma: comparison among primary tumors, tumors resistant to brachytherapy, tumors with liver metastases, and liver metastases.
Ben Simon GJ; Abulafia A; Pe'er J
Curr Eye Res; 2006 Mar; 31(3):251-7. PubMed ID: 16531282
[TBL] [Abstract][Full Text] [Related]
2. Cripto-1 expression in uveal melanoma: an immunohistochemical study.
Mallikarjuna K; Vaijayanthi P; Krishnakumar S
Exp Eye Res; 2007 Jun; 84(6):1060-6. PubMed ID: 17412323
[TBL] [Abstract][Full Text] [Related]
3. Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas.
Kaiserman N; Kaiserman I; Hendler K; Frenkel S; Pe'er J
Br J Ophthalmol; 2009 Sep; 93(9):1167-71. PubMed ID: 19570767
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target.
All-Ericsson C; Girnita L; Seregard S; Bartolazzi A; Jager MJ; Larsson O
Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):1-8. PubMed ID: 11773005
[TBL] [Abstract][Full Text] [Related]
5. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study.
Mallikarjuna K; Pushparaj V; Biswas J; Krishnakumar S
Curr Eye Res; 2007 Mar; 32(3):281-90. PubMed ID: 17453948
[TBL] [Abstract][Full Text] [Related]
6. Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation.
Krohn J; Monge OR; Skorpen TN; Mørk SJ; Dahl O
Eye (Lond); 2008 Nov; 22(11):1398-403. PubMed ID: 17585309
[TBL] [Abstract][Full Text] [Related]
7. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
8. Possible implications of MCAM expression in metastasis and non-metastatic of primary uveal melanoma patients.
Beutel J; Wegner J; Wegner R; Ziemssen F; Nassar K; Rohrbach JM; Hilgers RD; Lüke M; Grisanti S
Curr Eye Res; 2009 Nov; 34(11):1004-9. PubMed ID: 19958117
[TBL] [Abstract][Full Text] [Related]
9. HLA expression in choroidal melanomas: correlation with clinicopathological features.
Krishnakumar S; Abhyankar D; Lakshmi SA; Pushparaj V; Shanmugam MP; Biswas J
Curr Eye Res; 2004 Jun; 28(6):409-16. PubMed ID: 15512948
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of various biological parameters, including expression of survivin, between primary and metastatic human colonic adenocarcinomas.
Agui T; McConkey DJ; Tanigawa N
Anticancer Res; 2002; 22(3):1769-76. PubMed ID: 12168867
[TBL] [Abstract][Full Text] [Related]
11. Expression of p53-induced apoptosis effector PERP in primary uveal melanomas: downregulation is associated with aggressive type.
Paraoan L; Gray D; Hiscott P; Ebrahimi B; Damato B; Grierson I
Exp Eye Res; 2006 Oct; 83(4):911-9. PubMed ID: 16784742
[TBL] [Abstract][Full Text] [Related]
12. Survivin expression and its relationship with apoptosis and prognosis in nasal and paranasal sinus carcinomas.
Zhang Y; Huang D; Yu G
Acta Otolaryngol; 2005 Dec; 125(12):1345-50. PubMed ID: 16303685
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of chemokine receptors on uveal melanoma cells and their metastases.
Li H; Alizadeh H; Niederkorn JY
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):636-43. PubMed ID: 18235009
[TBL] [Abstract][Full Text] [Related]
14. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma.
Kleinberg L; Flørenes VA; Silins I; Haug K; Trope CG; Nesland JM; Davidson B
Cancer; 2007 Jan; 109(2):228-38. PubMed ID: 17167759
[TBL] [Abstract][Full Text] [Related]
15. Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers.
Khatib N; Pe'er J; Ortenberg R; Schachter J; Frenkel S; Markel G; Amer R
Invest Ophthalmol Vis Sci; 2011 Dec; 52(13):9368-72. PubMed ID: 22039239
[TBL] [Abstract][Full Text] [Related]
16. Survivin protein in UVB induced apoptosis of melanoma cells and in melanoma progression.
Zhang H
Oncol Rep; 2005 Jun; 13(6):1121-6. PubMed ID: 15870931
[TBL] [Abstract][Full Text] [Related]
17. Characterizing the involvement of the nuclear factor-kappa B (NF kappa B) transcription factor in uveal melanoma.
Dror R; Lederman M; Umezawa K; Barak V; Pe'er J; Chowers I
Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):1811-6. PubMed ID: 19892878
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients.
Haritoglou I; Wolf A; Maier T; Haritoglou C; Hein R; Schaller UC
Ophthalmologica; 2009; 223(4):239-43. PubMed ID: 19270465
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of survivin expression enhances sensitivity of cultured uveal melanoma cells to cisplatin treatment.
Li H; Niederkorn JY; Neelam S; Alizadeh H
Exp Eye Res; 2006 Jul; 83(1):176-82. PubMed ID: 16584731
[TBL] [Abstract][Full Text] [Related]
20. MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment.
Bérubé M; Deschambeault A; Boucher M; Germain L; Petitclerc E; Guérin SL
Mol Vis; 2005 Dec; 11():1101-11. PubMed ID: 16379022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
